Lusutrombopag

Lusutrombopag is a prescription medication indicated for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a procedure.

• Lusutrombopag is available under the following different brand names: Mulpleta

Common side effects of Lusutrombopag include:

• headache

Serious side effects of Lusutrombopag include:

• portal vein thrombosis

Rare side effects of Lusutrombopag include:

• none

Seek medical care or call 911 at once if you have the following serious side effects:

• Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors;
• Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights;
• Serious heart symptoms include fast, irregular, or pounding heartbeats; fluttering in the chest; shortness of breath; sudden dizziness, lightheadedness, or passing out.

This is not a complete list of side effects and other serious side effects or health problems that may occur as a result of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.

Adult dosage

Tablet

• 3 mg

Thrombocytopenia

• Begin dosing 8-14 days prior to the scheduled procedure
• Patients should undergo the procedure 2-8 days after the last dose
• Recommended dose: 3 mg orally every day for 7 days

Dosage Considerations – Should be Given as Follows:

• See “Dosages”

If your medical doctor is using this medicine to treat your pain, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, healthcare provider, or pharmacist first.

• Lusutrombopag has severe interactions with no other drugs.
• Lusutrombopag has serious interactions with no other drugs.
• Lusutrombopag has moderate interactions with no other drugs.
• Lusutrombopag has minor interactions with no other drugs.

This information does not contain all possible interactions or adverse effects. Visit the RxList Drug Interaction Checker for any drug interactions. Therefore, before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you and share this information with your doctor and pharmacist. Check with your healthcare professional or doctor for additional medical advice, or if you have health questions, concerns.

Contraindications

• None

Effects of drug abuse

• None

Short-Term Effects

• See “What Are Side Effects Associated with Using Lusutrombopag?”

Long-Term Effects

• See “What Are Side Effects Associated with Using Lusutrombopag?”

Cautions

• Thrombotic or thromboembolic complications
• Thrombopoietin (TPO) receptor agonists, such as Lusutrombopag, have been associated with thrombotic and thromboembolic complications (eg, portal vein thrombosis) in patients with chronic liver disease
• Consider the potential increased thrombotic risk when administering the drug to patients with known risk factors for thromboembolism (eg, genetic prothrombotic conditions including factor V Leiden, prothrombin 20210A, antithrombin deficiency, or protein C or S deficiency)
• In patients with ongoing or prior thrombosis or absence of hepatopetal blood flow, use lusutrombopag if the potential benefits justify the potential risks
• Lusutrombopag should not be administered to patients with chronic liver disease in order to normalize platelet counts

Pregnancy and Lactation

• There are no available data on use in pregnant women to inform a drug-associated risk
• Lactation
  • There is no information on the presence of lusutrombopag in human milk or its effects on the breastfed child and milk production
  • Drug was present in the milk of lactating rats
  • Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or any underlying maternal condition
  • Clinical considerations
    • Lactating women should interrupt breastfeeding and pump and discard breast milk during treatment and for 28 days after the last dose in order to minimize exposure to a breastfed child